National patient safety alert issued for GLP-1 receptor agonists

The alert warns healthcare providers not to switch between brands or double up on lower-dose preparations when the higher dose is unavailable.
Man self injecting with blue pen
The drugs impacted by shortages include semaglutide (Ozempic; Rybelsus); dulaglutide (Trulicity); liraglutide (Saxenda; Victoza) and exenatide (Byetta; Bydureon)

Shutterstock.com

The UK government has said it expects all NHS and private healthcare providers to follow national guidance to restrict use of semaglutide in patients with type 2 diabetes mellitus (T2DM), amid ongoing shortages.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated